Previous close | 26.97 |
Open | 26.90 |
Bid | 0.00 x 1400 |
Ask | 0.00 x 900 |
Day's range | 25.16 - 27.36 |
52-week range | 19.59 - 46.16 |
Volume | |
Avg. volume | 461,895 |
Market cap | 4.004B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.71 |
Earnings date | 09 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 40.50 |
CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a member of its board of directors. Mr. Varma succeeds Morris Birnbaum, M.D., Ph.D., who announced that he is retiring from his role as Senior Vice President and Chief Scientific Officer of Internal Medicine at Pfizer Inc., and will therefore be stepping
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8 at 10:30 am ET. The live webcast of the fireside chat can be accessed on the investor relations section of the Cerevel Therapeutics website here. A rep
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...